QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.106.029504v1 71/4/1051    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wiltshire, T. Articles by Wang, W. Search for Related Content PubMed PubMed Citation Articles by Wiltshire, T. Articles by Wang, W.

BRCA1 Contributes to Cell Cycle Arrest and Chemoresistance in Response to the Anticancer Agent Irofulven

Department of Microbiology, Immunology and Cell Biology (T.W., E.R., W.W.), Mary Babb Randolph Cancer Center (J.S., Y.W., E.R., W.W.), Department of Neurobiology and Anatomy (G.W.K.), and Department of Pathology (S.L.W.), West Virginia University School of Medicine, Morgantown, West Virginia

Tumor suppressor gene BRCA1 is frequently mutated in familial breast and ovarian cancer. BRCA1 plays pivotal roles in maintaining genomic stability by interacting with numerous proteins in cell cycle control and DNA repair. Irofulven (6-hydroxymethylacylfulvene, HMAF, MGI 114, NSC 683863) is one of a new class of anticancer agents that are analogs of mushroom-derived illudin toxins. Preclinical studies and clinical trials have demonstrated that irofulven is effective against several tumor cell types. The exact nature of irofulven-induced DNA damage is not completely understood. We demonstrated previously that irofulven activates ATM and its targets, NBS1, SMC1, CHK2, and p53. In this study, we hypothesize that irofulven induces DNA double-strand breaks and that BRCA1 may affect chemosensitivity by controlling cell cycle checkpoints, DNA repair, and genomic stability in response to irofulven treatment. We observed that irofulven induces the formation of chromosome breaks and radials and the activation and foci formation of -H2AX, BRCA1, and RAD51. We also provided evidence that irofulven induces the generation of DNA double-strand breaks. By using BRCA1-deficient or -proficient cells, we demonstrated that in response to irofulven, BRCA1 contributes to the control of S and G₂/M cell cycle arrest and is critical for repairing DNA double-strand breaks and for RAD51-dependent homologous recombination. Furthermore, we found that BRCA1 deficiency results in increased chromosome damage and chemosensitivity after irofulven treatment.

Address correspondence to: Dr. Weixin Wang, Mary Babb Randolph Cancer Center, West Virginia University, 1842 Health Sciences South, P.O. Box 9300, Morgantown, WV 26506-9300. E-mail: wwang{at}hsc.wvu.edu